Kumar, Princy <br/><br/>
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.  [electronic resource] 

 -  BMC infectious diseases  Jun 2013 
 - 269 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2334 
<br/><br/><label>Standard No.: </label>10.1186/1471-2334-13-269  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Alkynes<br/>Anti-HIV Agents--therapeutic use<br/>Benzoxazines--therapeutic use<br/>Biomarkers--blood<br/>C-Reactive Protein--metabolism<br/>Carbamates--therapeutic use<br/>Cyclopropanes<br/>Dideoxynucleosides--therapeutic use<br/>Drug Combinations<br/>Female<br/>Fibrin Fibrinogen Degradation Products--metabolism<br/>Fibrinogen--metabolism<br/>Furans<br/>HIV Infections--blood<br/>Humans<br/>Interleukin-6--blood<br/>Lamivudine--therapeutic use<br/>Male<br/>Middle Aged<br/>Organophosphates--therapeutic use<br/>Plasminogen--metabolism<br/>Prospective Studies<br/>Ritonavir--therapeutic use<br/>Sulfonamides--therapeutic use<br/>Vascular Cell Adhesion Molecule-1--blood<br/>Young Adult